We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Nasal polyps
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In patients with asthma, nasal polyps and other similar diseases, the chemical messenger interleukin-5 (IL-5) in the body is known to have an important role in causing disease - blocking the IL-5 message improves disease control and can lead to clinical remission. IL-5 is often thought to work through its actions on a type of immune cell called eosinophils, but there is evidence it may also have important actions on other types of immune cells. In particular it appears to have actions on antibody-producing B cells. This study will investigate how IL-5 affects antibody expression by B cells in the nose using samples collected from patients undergoing removal of tissue samples from the nose for clinical reasons.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Inability to give consent2. Previous rituximab treatment (ever)3. Chemotherapy with preceding 6 months4. Cystic fibrosis5. Pregnancy or breastfeeding6. Known current COVID infection/TB infection
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Paul
Pfeffer
+44 (0)2034165000
Paul.pfeffer1@nhs.net
The study is sponsored by Queen Mary University of London and funded by GlaxoSmithKline; Grant Codes: 220761.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 60796
You can print or share the study information with your GP/healthcare provider or contact the research team directly.